Clinical trial
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving…
NCT00107263 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00107263 |
|---|---|
| Title | Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer |
| Official title | A Randomized, Controlled, Open-Label Trial of Empiric Prophylactic vs. Delayed Use of Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women With Breast Cancer Initiating Therapy With Letrozole After Tamoxifen |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Osteoporosis |
| Intervention type | Drug |
| Interventions | letrozole, zoledronic acid |
| Enrollment | 558 |
| Start date | Jan 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Aug 1, 2012 |
| First posted | Apr 6, 2005 |
| Last update posted | Dec 6, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: